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Aim: To explore the antibacterial spectrum of ozenoxacin and compare its in vitro activity with that of
other antibacterial agents. Materials & methods: In 2010, 10,054 isolates were collected from 128 centers
worldwide. Minimum inhibitory concentrations against Gram-positive and Gram-negative isolates were
determined for 23 and 13 antibacterial agents, respectively. Results: Ozenoxacin exhibited high in vitro
activity against susceptible, and methicillin- or levofloxacin-resistant, Gram-positive bacteria. Ozenoxacin
was one or two dilutions less active against Enterobacteriaceae isolates, except for Escherichia coli, than
other quinolones. Conclusion: Ozenoxacin is a potent antimicrobial agent mainly against susceptible and
resistant strains of Gram-positive isolates (staphylococci and streptococci), and shows activity against some
Gram-negative isolates.
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Impetigo is a common bacterial skin infection affecting children and adults that is caused by Staphylococcus aureus
or Streptococcus pyogenes. It is the most common bacterial skin infection in children aged 2–5 years [1,2].
Impetigo is commonly treated with topically applied antibacterial agents such as mupirocin, fusidic acid and
retapamulin [1–5]. A recent evidence-based review supported the clinical efficacy of mupirocin and fusidic acid
for treatment of impetigo [5]. However, in some cases, development of resistant isolates limits the uses of these
agents [1,5].
An alternative option for treating impetigo in children and adults is a 1% topical cream formulation of ozenoxacin,
a nonfluorinated quinolone with bactericidal activity [6], which was recently approved in several countries world-
wide [7–10]. Approval of ozenoxacin was granted based on demonstrable clinical benefit in two large Phase III
trials of impetigo involving adults and children from 2 months of age [11,12]. Rapid eradication of bacterial load is
important in impetigo to hasten symptom resolution and limit person-to-person transmission of infection.
Early in vitro characterization of ozenoxacin found that it was 3- to 321-fold more active than other quinolones
against quinolone-susceptible and quinolone-resistant Gram-positive bacteria [13]. A subsequent and more com-
prehensive study showed that ozenoxacin has potent antibacterial activity against staphylococci and streptococci,
irrespective of their levofloxacin susceptibility status [14].
This article presents additional surveillance study data generated during development of ozenoxacin. The
antibacterial activity of ozenoxacin against Gram-positive and Gram-negative clinical isolates was compared with
that of other topical and systemic antibiotics used in the treatment of skin and soft tissue infections (SSTIs). As
it had yet to be decided at the time of the study whether ozenoxacin was to be developed as a systemic (oral
or intravenous) and/or topical formulation, in order to ascertain its full microbiological profile, its antibacterial
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activity was also investigated against Gram-positive and Gram-negative bacteria causing respiratory tract infections
(RTIs) and urinary tract infections (UTIs).
Methods
Clinical isolates collection
During 2010, a total of 10,054 bacterial isolates were collected from 128 centers, with some sites collecting isolates
from more than one hospital. Centers were located in the USA (n = 28); Germany (n = 15); France (n = 8); Turkey
(n = 8); the United Kingdom (n = 7); Spain (n = 6); Italy (n = 5); Belgium, Canada, Greece, Portugal and South
Africa (n = 4 each); Argentina, Australia, Austria, Czech Republic, Japan, Philippines, Slovak Republic, Thailand
(n = 2 each); and Hong Kong, Hungary, Ireland, Israel, Malaysia, New Zealand, Poland, Romania, South Korea,
Sweden, Switzerland, Taiwan and The Netherlands (n = 1 each).
Isolates were derived from SSTIs (44.8%), RTIs (38.1%), UTIs (1.3%) unknown (8.4%) or other (7.5%)
sources. Taxonomic classification of isolates is summarized in Table 1. Isolates were identified following standard
microbiological methods, including biochemical test and mass spectrometry (MALDI TOF MS).
Minimum inhibitory concentration determination
Minimum inhibitory concentration (MIC) was determined using broth microdilution methods as recommended
by the Clinical and Laboratory Standards Institute (CLSI) [15–17].
Susceptibility was determined using breakpoints set by the CLSI [15,17], except that British Society for Antimi-
crobial Chemotherapy (BSAC) breakpoints were used for fusidic acid and mupirocin against staphylococci [18].
S. aureus ATCC 29213, S. pneumoniae ATCC 49619, Escherichia coli ATCC 25922 and E. coli ATCC 35218
isolates were used for quality control. All quality control results were within the ranges specified by the CLSI [17,19].
Concentrations of antibacterial agent tested for each isolate are shown in Table 2.
Results
Classification of clinical isolates
Gram-positive bacteria included in the study as principle pathogens were: coagulase-negative staphylococci (CNS),
S. aureus, β-haemolytic streptococci, viridans streptococci, S. pneumoniae and enterococci (Table 1). A high
proportion of Gram-positive isolates (69.5% of CNS [618/889]; 63.3% of S. aureus [1518/2398]; 78.8% of
β-haemolytic streptococci [953/1210]; 66.2% of viridans streptococci [353/533]; and 50.6% of enterococci
[84/166]) were derived from SSTIs.
Gram-negative bacteria included in the study as principle pathogens were: Enterobacteriaceae (n = 3190),
Haemophilus spp. (n = 548) and Moraxella catarrhalis (n = 180) (Table 1). A high proportion of Gram-negative
isolates classified as Haemophilus spp. (95.8%; 525/548) or M. catarrhalis (93.9%; 169/180) were derived from





Ozenoxacin was highly active against staphylococci with a MIC90 of 0.25 mg/l against S. aureus and all CNS
isolates (Table 3). In general, ozenoxacin had high activity against Gram-positive bacteria irrespective of their
resistance/susceptibility to methicillin or nonsusceptibility/susceptibility to levofloxacin.
A comparison of MIC90 values in SSTI-derived isolates (Table 4) demonstrated that ozenoxacin (0.5 mg/l)
was more active against CNS isolates than 19 of 22 comparator agents tested including vancomycin and linezolid
(2 mg/l); moxifloxacin (4 mg/l); amoxicillin-clavulanate and teicoplanin (8 mg/l); levofloxacin (>8 mg/l); fusidic
acid and trimethoprim-sulfamethoxazole (16 mg/l); meropenem (>16 mg/l); ampicillin, neomycin and tetracycline
(32 mg/l); ceftriaxone and clarithromycin (>32 mg/l); penicillin and piperacillin/tazobactam (64 mg/l); and
mupirocin, ceftazidime and cefuroxime (>64 mg/l). Retapamulin was the only comparator tested to have a MIC90
value (0.12 mg/l) lower than that of ozenoxacin, while tigecycline and daptomycin each had a MIC90 value
(0.5 mg/l) equivalent to that of ozenoxacin.
Against S. aureus specifically (Table 4), ozenoxacin was equally as active as mupirocin, retapamulin, tigecycline
and trimethoprim-sulfamethoxazole (MIC90 of 0.25 mg/l), and was more active than 18 of 22 comparator
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Table 1. Categorization of isolates (n = 10,054) from skin and soft tissue infections, respiratory tract infections, urinary
tract infections and other or unknown sources (≥ 10 in ≥ 1 category).
Group Pathogen SSTI RTI UTI Unknown Other Total
Gram-positive
Coagulase-negative staphylococci (CNS) All CNS 618 106 1 146 18 889
Staphylococcus capitis 30 8 12 3 53
Staphylococcus epidermidis 365 47 86 9 507
Staphylococcus haemolyticus 76 18 11 1 106
Staphylococcus hominis 48 20 22 4 94
Staphylococcus lugdunensis 53 4 6 63
Staphylococcus pettenkoferi 10 1 3 14
Staphylococcus warneri 7 4 4 1 16
Staphylococcus aureus Staphylococcus aureus 1518 666 1 196 17 2398
-haemolytic streptococci All -haemolytic streptococci 953 118 5 127 7 1210
Streptococcus agalactiae 271 11 5 37 3 327
Streptococcus dysgalactiae 172 28 21 1 222
Streptococcus pyogenes 507 78 69 3 657
Viridans streptococci All Viridans streptococci 353 64 1 108 7 533
Streptococcus anginosus 91 11 14 1 117
Streptococcus constellatus 60 6 4 70
Streptococcus gallolyticus 38 2 1 19 60
Streptococcus intermedius 15 4 3 22
Streptococcus mitis 29 13 21 2 65
Streptococcus oralis 39 8 12 1 60
Streptococcus parasanguinis 18 4 4 26
Streptococcus salivarius 23 7 10 1 41
Streptococcus sanguinis 10 1 7 1 19
Streptococcus pneumoniae Streptococcus pneumoniae 63 843 18 3 927
Enterococci All Enterococci 84 8 41 26 7 166
Enterococcus faecalis 81 7 39 26 6 159
Gram-negative
Enterobacteriaceae All Enterobacteriaceae 895 1329 70 208 688 3190
Citrobacter freundii 50 33 8 4 38 133
Citrobacter koseri 40 34 10 1 34 119
Klebsiella aerogenes 54 45 4 4 51 158
Enterobacter cloacae 73 74 2 5 65 219
Escherichia coli 287 508 17 5 234 1051
Klebsiella oxytoca 51 100 6 40 197
Klebsiella pneumoniae 94 350 11 2 87 544
Morganella morganii 144 44 3 2 40 233
Salmonella spp. 15 5 3 106 34 163
Serratia marcescens 61 117 4 6 44 232
Shigella flexneri 1 2 32 5 40
Shigella sonnei 3 2 34 2 41
Other Gram-negative bacteria Haemophilus spp. 11 525 3 9 548
Haemophilus influenzae 3 458 2 7 470
Haemophilus parainfluenzae 8 62 1 2 73
Moraxella catarrhalis 4 169 6 1 180
Neisseria gonorrhoeae 2 7 4 13
RTI: Respiratory tract infection; SSTI: Skin and soft tissue infection; UTI: Urinary tract infection.
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Table 2. Concentrations of antibacterial agent tested for each bacteria.









Enterobacteriaceae Haemophilus spp. Neisseria gonorrhoeae
Ozenoxacin 0.001–2 0.001–2 0.001–2 0.001–2 0.001–2 0.001–2
Mupirocin 0.03–64 0.03–64
Fusidic acid 0.03–64 0.03–64
Levofloxacin 0.004–8 0.03–64 0.03–64 0.004–8 0.008–16 0.004–4
Moxifloxacin 0.004–8 0.015–32 0.015–32 0.004–8 0.008–16 0.004–4
Ciprofloxacin 0.002–4 0.004–4
Ampicillin 0.015–32 0.008–16 0.015–32 0.015–32 0.008–16
Amoxicillin-
clavulanate
0.015–32 0.008–16 0.008–16 0.015–32 0.015–32
Cefuroxime 0.03–64 0.008–16 0.008–16 0.03–64 0.015–16 0.008–1
Ceftriaxone 0.03–32 0.004–8 0.004–8 0.015–32 0.004–8 0.004–0.5
Ceftazidime 0.03–64 0.015–16 0.015–16 0.03–64 0.008–16
Clarithromycin 0.03–32 0.015–32 0.015–32 0.015–32
Daptomycin 0.015–32 0.015–32 0.015–16
Linezolid 0.015–32 0.015–32 0.015–32
Meropenem 0.008–16 0.008–16 0.008–16 0.004–8 0.008–16
Neomycin 0.03–64 0.03–64 0.03–64




0.03–64 0.015–32 0.03–64 0.06–128 0.03–64
Retapamulin 0.008–16 0.008–16
Teicoplanin 0.015–32 0.015–32 0.015–32
Tetracycline 0.03–64 0.03–64 0.03–64 0.03–64 0.015–8
Tigecycline 0.004–4 0.004–4 0.002–4 0.004–8 0.002–4
Trimethoprim-
sulfamethoxazole
0.015–32 0.015–32 0.015–32 0.015–32
Vancomycin 0.03–64 0.03–32 0.015–32 0.001–2
antibacterial agents tested that had MIC90 values of 0.5 mg/l (fusidic acid and daptomycin); 1 mg/l (teicoplanin and
vancomycin); 2 mg/l (linezolid); 4 mg/l (moxifloxacin); >8 mg/l (levofloxacin); 16 mg/l (amoxicillin/clavulanic
acid and meropenem); 32 mg/l (tetracycline); >32 mg/l (ampicillin, ceftriaxone and clarithromycin); 64 mg/l
(penicillin and piperacillin-tazobactam); and >64 mg/l (ceftazidime, cefuroxime and neomycin).
Ozenoxacin was consistently among the most active antibacterial agents (as measured by MIC90) against indi-
vidual CNS spp. derived from SSTIs (Table 4). Ozenoxacin was the most active agent against Staphylococcus capitis
(0.06 mg/l) and S. lugdunensis (0.015 mg/l). Ozenoxacin was the fourth most active agent against S. epidermidis
(1 mg/l) after retapamulin, daptomycin and tigecycline in order. Ozenoxacin and mupirocin were equal-second
most active agents against S. haemolyticus (0.25 mg/l) after retapamulin. Ozenoxacin was the third most active
agent against S. hominis (1 mg/l) after retapamulin and daptomycin.
Resistance rates to fusidic acid identified in several staphylococcal species (S. aureus spp. [n = 2398]: 6.5%;
methicillin-resistant S. aureus [MRSA; n = 1053]: 8.5%; methicillin-susceptible S. aureus [MSSA; n = 1345]: 5.1%;
and CNS spp. [n = 889]: 24.6%) were higher when antimicrobial activity was tested in isolates derived from SSTIs
(S. aureus spp. [n = 1518]: 7.8%; CNS spp. [n = 618]: 24.1%; S. capitis [n = 30]: 16.7%; S. epidermidis [n = 365]:
26.8%; S. haemolyticus [n = 76]: 26.3%; and S. hominis [n = 48]: 33.3%). Resistance rates to mupirocin in these
same species were (S. aureus spp.: 4.8%; MRSA: 9.0%; MSSA: 1.6%; and CNS spp.: 27.8%); and in isolates derived
from SSTIs were (S. aureus spp.: 4.7%; CNS spp.: 27.7%; S. capitis: 6.7%; S. epidermidis: 40.5%; S. haemolyticus:
5.3%; and S. hominis: 22.9%).
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Table 3. Summary minimum inhibitory concentration data of ozenoxacin stratified by methicillin
resistance/susceptibility and/or levofloxacin susceptibility/nonsusceptibility for Gram-positive bacteria
(staphylococci, streptococci and enterococci).
Pathogen Levofloxacin susceptibility n Ozenoxacin MIC (mg/l)
MIC50 MIC90 Range
Staphylococcus aureus All 2398 0.004 0.25 ≤0.001−2
Levofloxacin nonsusceptible 877 0.12 0.25 0.002−2
Levofloxacin susceptible 1521 0.004 0.004 ≤0.001−2
– Methicillin-resistant S. aureus (MRSA) All 1053 0.12 0.25 ≤0.001−2
Levofloxacin nonsusceptible 769 0.12 0.25 ≤0.001−2
Levofloxacin susceptible 284 0.004 0.008 0.002−2
– Methicillin-susceptible S. aureus (MSSA) All 1345 0.004 0.008 ≤0.001−2
Levofloxacin nonsusceptible 108 0.12 1 0.004−2
Levofloxacin susceptible 1237 0.004 0.004 ≤0.001−0.5
Coagulase-negative staphylococci (CNS) All 889 0.015 0.25 ≤0.001−2
Levofloxacin nonsusceptible 395 0.12 1 0.03−2
Levofloxacin susceptible 494 0.008 0.015 ≤0.001−0.12
– Methicillin-resistant CNS All 500 0.12 1 ≤0.001−2
Levofloxacin nonsusceptible 346 0.12 1 0.03−2
Levofloxacin susceptible 154 0.008 0.015 ≤0.001−0.03
– Methicillin-susceptible CNS All 389 0.008 0.12 0.002−2
Levofloxacin nonsusceptible 49 0.12 2 0.03−2
Levofloxacin susceptible 340 0.008 0.015 0.002−0.12
Staphylococcus capitis All 53 0.008 0.12 0.002−0.12
Levofloxacin nonsusceptible 13 0.06 0.12 0.03−0.12
Levofloxacin susceptible 40 0.008 0.008 0.002−0.015
– Methicillin-resistant S. capitis All 23 0.008 0.12 0.004−0.12
Levofloxacin nonsusceptible 11 0.06 0.12 0.03−0.12
Levofloxacin susceptible 12 0.008 0.008 0.004−0.008
– Methicillin-susceptible S. capitis All 30 0.008 0.008 0.002−0.12
Levofloxacin nonsusceptible 2 0.06 0.12 0.03−0.12
Levofloxacin susceptible 28 0.008 0.008 0.002−0.15
Staphylococcus epidermidis All 507 0.06 1 ≤0.001−2
Levofloxacin nonsusceptible 265 0.12 2 0.03−2
Levofloxacin susceptible 242 0.008 0.015 ≤0.001−0.03
– Methicillin-resistant S. epidermidis All 337 0.12 1 ≤0.001−2
Levofloxacin nonsusceptible 237 0.12 2 0.03−2
Levofloxacin susceptible 100 0.008 0.015 ≤0.001−0.015
– Methicillin-susceptible S. epidermidis All 170 0.008 0.12 0.002−2
Levofloxacin nonsusceptible 28 0.12 2 0.06−2
Levofloxacin susceptible 142 0.008 0.015 0.002−0.03
Staphylococcus haemolyticus All 106 0.12 0.25 0.002−1
Levofloxacin nonsusceptible 67 0.12 0.25 0.03−1
Levofloxacin susceptible 39 0.004 0.008 0.002−0.008
– Methicillin-resistant S. haemolyticus All 73 0.12 0.25 0.004−1
Levofloxacin nonsusceptible 62 0.12 0.25 0.06−1
Levofloxacin susceptible 11 0.004 0.008 0.004−0.008
– Methicillin-susceptible S. haemolyticus All 33 0.008 0.12 0.002−0.25
Levofloxacin nonsusceptible 5 0.12 0.25 0.03−0.25
Levofloxacin susceptible 28 0.004 0.008 0.002−0.008
MIC: Minimum inhibitory concentration.
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Table 3. Summary minimum inhibitory concentration data of ozenoxacin stratified by methicillin
resistance/susceptibility and/or levofloxacin susceptibility/nonsusceptibility for Gram-positive bacteria
(staphylococci, streptococci and enterococci) (cont.).
Pathogen Levofloxacin susceptibility n Ozenoxacin MIC (mg/l)
MIC50 MIC90 Range
Staphylococcus hominis All 94 0.008 0.25 0.002−2
Levofloxacin nonsusceptible 33 0.12 2 0.03−2
Levofloxacin susceptible 61 0.008 0.008 0.002−0.12
– Methicillin-resistant S. hominis All 51 0.06 1 0.004−2
Levofloxacin nonsusceptible 29 0.12 2 0.03−2
Levofloxacin susceptible 22 0.008 0.015 0.004−0.015
– Methicillin-susceptible S. hominis All 43 0.008 0.06 0.002−1
Levofloxacin nonsusceptible 4 0.12 1 0.06−1
Levofloxacin susceptible 39 0.008 0.008 0.002−0.12
Staphylococcus lugdunensis All 63 0.015 0.015 0.004−0.25
Levofloxacin nonsusceptible 3 0.25 0.25 0.12−0.25
Levofloxacin susceptible 60 0.015 0.015 0.004−0.03
– Methicillin-resistant S. lugdunensis All 2 0.008 0.12 0.008−0.12
Levofloxacin nonsusceptible 1 0.12 0.12 0.12−0.12
Levofloxacin susceptible 1 0.008 0.008 0.008−0.008
– Methicillin-susceptible S. lugdunensis All 61 0.015 0.015 0.004−0.25
Levofloxacin nonsusceptible 2 0.25 0.25 0.25−0.25
Levofloxacin susceptible 59 0.015 0.03 0.004−0.03
Staphylococcus pettenkoferi All 14 0.5 0.5 0.004−1
Levofloxacin nonsusceptible 10 0.5 1 0.12−1
Levofloxacin susceptible 4 0.008 0.03 0.004−0.03
– Methicillin-resistant S. pettenkoferi All 4 0.5 1 0.03−1
Levofloxacin nonsusceptible 3 0.5 1 0.5−1
Levofloxacin susceptible 1 0.03 0.03 0.03−0.03
– Methicillin-susceptible S. pettenkoferi All 10 0.12 0.5 0.004−1
Levofloxacin nonsusceptible 7 0.5 1 0.12−1
Levofloxacin susceptible 3 0.008 0.008 0.004−0.008
– Staphylococcus warneri All 16 0.008 0.015 0.004−0.015
Levofloxacin nonsusceptible 3 0.008 0.015 0.008−0.015
Levofloxacin susceptible 13 0.008 0.015 0.004−0.015
-haemolytic streptococci All 1210 0.03 0.03 0.004−2
– Streptococcus agalactiae All 327 0.03 0.06 0.008−1
Levofloxacin nonsusceptible 8 1 1 0.25−1
Levofloxacin susceptible 319 0.03 0.06 0.008−0.12
– Streptococcus dysgalactiae All 222 0.03 0.03 0.008−0.25
Levofloxacin nonsusceptible 5 0.25 0.25 0.06−0.25
Levofloxacin susceptible 217 0.015 0.03 0.008−0.25
– Streptococcus pyogenes All 657 0.015 0.03 0.004−2
Levofloxacin nonsusceptible 2 0.06 2 0.06−2
Levofloxacin susceptible 655 0.015 0.03 0.004−0.12
Viridans streptococci All 533 0.03 0.06 ≤0.001−2
– Streptococcus anginosus All 117 0.015 0.03 ≤0.001−0.06
– Streptococcus constellatus All 70 0.015 0.03 ≤0.001−0.06
– Streptococcus cristatus All 3 0.015 0.03 0.015−0.03
– Streptococcus equinus All 6 0.015 0.06 0.015−0.06
MIC: Minimum inhibitory concentration.
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Table 3. Summary minimum inhibitory concentration data of ozenoxacin stratified by methicillin
resistance/susceptibility and/or levofloxacin susceptibility/nonsusceptibility for Gram-positive bacteria
(staphylococci, streptococci and enterococci) (cont.).
Pathogen Levofloxacin susceptibility n Ozenoxacin MIC (mg/l)
MIC50 MIC90 Range
– Streptococcus gallolyticus All 60 0.03 0.06 0.008−2
Levofloxacin nonsusceptible 4 0.12 2 0.06−2
Levofloxacin susceptible 56 0.03 0.06 0.008−0.12
– Streptococcus intermedius All 22 0.015 0.03 0.004−0.06
– Streptococcus mitis All 65 0.03 0.06 0.015−0.5
Levofloxacin nonsusceptible 2 0.25 0.5 0.25−0.5
Levofloxacin susceptible 63 0.03 0.06 0.015−0.06
– Streptococcus oralis All 60 0.03 0.06 0.015−0.25
Levofloxacin nonsusceptible 2 0.25 0.25 0.25−0.25
Levofloxacin susceptible 58 0.03 0.06 0.015−0.06
– Streptococcus parasanguinis All 26 0.03 0.25 0.015−2
Levofloxacin nonsusceptible 4 0.25 2 0.06−2
Levofloxacin susceptible 22 0.03 0.03 0.015−0.06
– Streptococcus peroris All 13 0.03 0.06 0.015−1
Levofloxacin nonsusceptible 1 1 1 1−1
Levofloxacin susceptible 12 0.03 0.06 0.015−0.06
– Streptococcus salivarius All 41 0.03 0.06 0.015−0.06
– Streptococcus sanguinis All 19 0.03 0.06 0.015−0.06
Streptococcus pneumoniae All 927 0.03 0.03 ≤0.001−2
Levofloxacin nonsusceptible 11 0.25 2 0.06−2
Levofloxacin susceptible 916 0.03 0.03 ≤0.001−0.12
Penicillin nonsusceptible 96 0.03 0.03 0.008−2
Penicillin susceptible 831 0.03 0.03 ≤0.001−0.5
Enterococci All 166 0.06 1 ≤0.001−2
– Enterococcus faecalis All 159 0.06 1 ≤0.001−2
Levofloxacin nonsusceptible 48 1 1 0.06−2
Levofloxacin susceptible 111 0.03 0.06 ≤0.001−0.25
MIC: Minimum inhibitory concentration.
Streptococci & enterococci
Ozenoxacin was highly active against levofloxacin nonsusceptible/susceptible streptococci and Enterococcus spp.
(Table 3) with a MIC90 of 0.03 mg/l against combined β-haemolytic streptococci; 0.06 against combined viridans
streptococci; 0.03 mg/l against S pneumoniae; and 1 mg/l against enterococci including E. faecalis.
In SSTI-derived isolates (Table 4), ozenoxacin had the lowest or equal-lowest MIC90 compared with 22 other an-
tibacterial agents tested against the following bacteria: combined β-haemolytic streptococci, S. agalactiae, combined
viridans streptococci, S. anginosus, S. constellatus, S. oralis and S. pneumoniae. The activity of ozenoxacin against
remaining streptococci and enterococci was generally within one dilution of the most active compound. Against
combined β-haemolytic streptococci, ozenoxacin had the lowest MIC90 (0.03 mg/l) of all 23 antibacterial agents
tested. Meropenem, penicillin, amoxicillin-clavulanic acid, ceftriaxone, cefuroxime and retapamulin each had a
MIC90 of 0.06 mg/l, while ampicillin, teicoplanin and tigecycline each had a MIC90 of 0.012 mg/l. MIC90 values
for all other agents were higher than that of ozenoxacin: 0.25 mg/l for moxifloxacin, daptomycin, piperacillin-
tazobactam and trimethoprim-sulfamethoxazole; 0.5 mg/l for vancomycin; 1 mg/l for mupirocin, levofloxacin,
ceftazidime and linezolid; 4 mg/l for clarithromycin; 16 mg/l for fusidic acid; and 64 mg/l for tetracycline and
neomycin.
Against E. faecalis (Table 4), tigecycline (MIC90 of 0.12 mg/l) was the most active agent, followed by amoxicillin-
clavulanic acid and tetracycline (both 0.05 mg/dl), then ozenoxacin and ampicillin (both 1 mg/dl).
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Table 5. Summary minimum inhibitory concentration data of ozenoxacin for Gram-negative bacteria.
Pathogen n Ozenoxacin MIC (mg/l)
MIC50 MIC90 Range
All Enterobacteriaceae 3190 0.25 2 0.004−2
– Citrobacter braakii 11 1 2 0.06−2
– Citrobacter freundii 133 0.25 2 0.03−2
– Citrobacter koseri 119 0.06 0.12 0.015−2
– Klebsiella aerogenes 158 0.25 2 0.03−2
– Enterobacter asburiae 21 0.12 0.5 0.03−2
– Enterobacter cloacae 219 0.12 2 0.015−2
– Enterobacter kobei 11 0.25 2 0.03−2
– Escherichia coli 1051 0.06 2 0.004−2
– Klebsiella oxytoca 197 0.25 1 0.03−2
– Klebsiella pneumoniae 544 0.25 2 0.008−2
– Morganella morganii 233 0.25 2 0.03−2
– Salmonella spp. 163 0.12 0.5 0.015−2
– Serratia marcescens 232 1 2 0.004−2
– Shigella flexneri 40 0.03 0.5 0.008−2
– Shigella sonnei 41 0.03 0.25 0.008−2
Other Gram-negative bacteria
– Haemophilus spp. 548 0.004 0.03 ≤0.001−2
– Haemophilus influenza 470 0.004 0.015 ≤0.001−1
– Haemophilus parainfluenza 73 0.03 0.25 ≤0.001−2
– Moraxella catarrhalis 180 0.004 0.008 ≤0.001−0.03
– Neisseria gonorrheae 13 0.12 1 ≤0.001−2
MIC: Minimum inhibitory concentration.
Gram-negative bacteria
Enterobacteriaceae
Ozenoxacin had a MIC90 of more than 2 mg/l for combined species of the Enterobacteriaceae family, with values
ranging from 0.12 mg/l for Citrobacter koseri, 0.25 mg/l for Shigella sonnei, 0.5 mg/l for Enterobacter asburiae and
S. flexneri, 1 mg/l for Klebsiella oxytoca, and more than 2 mg/l for all remaining species (Table 5).
MIC values against Gram-negative bacteria derived from SSTIs were compared for ozenoxacin and 13 other
antibacterial agents. Based on MIC90, ozenoxacin was the most active quinolone against combined Enterobacte-
riaceae, E. cloacae, E. coli, K. pneumoniae and Morganella morganii. In contrast, ozenoxacin was the least active
quinolone against C. freundii, C. koseri, E. aerogenes, K. oxytoca and Serratia marcescens. However, the quinolones
were generally of similar activity with MIC90 values within one or two dilutions of each other.
For combined species of Enterobacteriaceae, the most active compounds (as measured by MIC90) were
meropenem (0.06 mg/l), tigecycline (2 mg/l) and ozenoxacin (>2 mg/l), followed by neomycin (4 mg/l),
ciprofloxacin (>4 mg/l), levofloxacin and moxifloxacin (each >8 mg/l). All other antibacterial agents had MIC90
values of 32 to >128 mg/l (Table 6).
Other Gram-negative bacteria
For other Gram-negative bacteria (Table 5), ozenoxacin was highly active against Haemophilus spp. (MIC90 of
0.03 mg/l), H. influenzae (0.015 mg/l) and Moraxella catarrhalis (0.008 mg/l), and was somewhat less active
against H. parainfluenzae (0.25 mg/l) and Neisseria gonorrhoeae (1 mg/l), although it was tested on only 13 N.
gonorrhoeae isolates.
Ozenoxacin and levofloxacin (MIC90 of 0.015 mg/l) were the second most active antibacterial agents against
H. influenzae after ceftriaxone (0.008 mg/l), followed by piperacillin/tazobactam (≤0.03 mg/l), moxifloxacin
(0.03 mg/l), meropenem (0.06 mg/l) and ceftazidime (0.12 mg/l); all other antibacterial agents had MIC90 values
of 0.5–16 mg/l.
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All quinolones were less active against H. parainfluenzae than H. influenzae. Ceftriaxone (MIC90 of 0.008 mg/l)
was the most active antibacterial agent against this species, followed by ceftazidime and meropenem (0.06 mg/l),
levofloxacin (0.12 mg/l), then ozenoxacin, moxifloxacin and piperacillin/tazobactam (0.25 mg/l); all other an-
tibacterial agents had MIC90 values of 1–16 mg/l.
Ozenoxacin and meropenem were the most active agents against M. catarrhalis (MIC90 of ≤0.008 mg/l),
followed by piperacillin/tazobactam (≤0.03 mg/l), levofloxacin and moxifloxacin (0.06 mg/l), and clarithromycin
(0.12 mg/l); all other agents had MIC90 values of 0.25–16 mg/l.
Discussion
A previously published study that compared the antimicrobial activity of ozenoxacin versus 17 antibacterial agents
in more than 2000 Gram-positive clinical isolates from SSTIs showed that ozenoxacin is a potent antimicrobial
agent against both staphylococci and streptococci, irrespective of levofloxacin susceptibility status [14]. The current
comparative study examined the antibacterial activity of ozenoxacin in Gram-positive and Gram-negative clinical
isolates derived mainly from SSTIs, RTIs and UTIs, which were stratified according to their methicillin and
levofloxacin susceptibility status. The antibacterial activity of ozenoxacin was compared with that of 22 other
antibacterial agents against approximately 4500 Gram-positive SSTI isolates, and with that of 13 other antibacterial
agents against approximately 900 Gram-negative SSTIs isolates and Gram-negative isolates from other sources
(e.g., RTIs, UTIs, etc).
Against Gram-positive isolates from SSTIs, ozenoxacin was highly active against staphylococci and streptococci,
confirming the results of previously published comparative studies [14]. Ozenoxacin had a lower MIC90 than
mupirocin and fusidic acid against the CNS isolates S. capitis, S. epidermidis, S. hominis and S. lugdunensis, and
against combined β-haemolytic streptococci, combined viridans streptococci, all other subspecies of streptococci,
and enterococci. Ozenoxacin was equally active as mupirocin (as measured by MIC90) against S. haemolyticus and
S. aureus. These results confirm and extend the previously reported results showing higher activity of ozenoxacin
compared with mupirocin and fusidic acid against staphylococci and streptococci [14].
Clinical breakpoints of antibiotics are calculated based on MIC distributions, and pharmacokinetic and phar-
macodynamic data (area under the curve of plasma concentrations). Because topical antibiotics are minimally
absorbed, clinical breakpoints cannot be determined. Instead, combined MIC distributions from multiple sources
and time periods are used to define epidemiological cutoffs that provide an indication of MICs for organisms with
acquired or mutational resistance mechanisms. The inferred breakpoint for mupirocin is 1/256 mg/l and applies
to topical nasal administration three-times daily. It is based on microbiological data (epidemiological cutoffs) and
clinical experience [20]. In the case of fusidic acid, breakpoints for Staphylococcus spp. are S ≤1 mg/l and R >1 mg/l
for an oral or IV dosage of 500 mg two- to three-times daily. The breakpoints are based on pharmacokinetic
data, microbiological data and clinical experience [21]. In the current study, BSAC disk diffusion breakpoints that
are harmonized with the European Committee on Antimicrobial Testing were used for susceptibility testing of
mupirocin and fusidic acid [18]. Disk diffusion tests with ozenoxacin have yet to be conducted but are planned.
According to the BSAC breakpoints in this study, the resistance rate of S. aureus to mupirocin and fusidic acid was
higher in MRSA isolates than in MSSA isolates (9.0 and 1.6% for mupirocin and 8.5 and 5.1% for fusidic acid,
respectively).
Fusidic acid, mupirocin or retapamulin are the main topical treatments recommended in Europe for treatment
of impetigo [22], although resistance of staphylococcal strains to these agents is becoming a concern. Resistance
to fusidic acid [23–27] and mupirocin [28–30] has been reported in Europe and may be increasing. Investigators in
Greece reported a sevenfold increase from 2013 to 2016 in the rate of mupirocin-resistant S. aureus strains among
community-associated staphylococcal infections (mainly impetigo cases), concurrent with a 1.9-fold increase in
resistance rates to fusidic acid [31], highlighting the need for alternatives. Ozenoxacin’s dual inhibitory activity against
DNA gyrase and topoisomerase IV, in addition to other characteristics such as a mutant prevention concentration
below that in skin, appear to protect it from the development of resistance [10].
Elsewhere, a Japanese comparative study of ozenoxacin with other antibacterial agents against cutaneous bacterial
isolates from pediatric patients reported MIC90 values for ozenoxacin of 0.12, ≤0.06 and ≤0.06 mg/l against
MRSA, MSSA and S. pyogenes isolates, respectively [32]. Respective MIC90 values for gentamicin against MRSA,
MSSA and S. pyogenes isolates in this same Japanese study were more than 128, 64 and 4 mg/l for SSTIs from adults
and 128, 16 and 4 mg/l for SSTIs from children. Gentamicin is used topically to treat SSTIs in some countries
10.2217/fmb-2019-0089 Future Microbiol. (Epub ahead of print) future science group
Microbiological profile of ozenoxacin Research Article
but was not included in the present study. The Japanese results highlight that ozenoxacin is markedly more active
than gentamicin against the most common Gram-positive bacteria found in SSTIs.
Another Japanese study showed that MICs of ozenoxacin against three levofloxacin-susceptible Propionibacterium
acnes strains (MIC of levofloxacin; ≤4 μg/ml) and three levofloxacin-resistant P. acnes strains (MIC of levofloxacin;
≥8 μg/ml) ranged from 0.03 to 0.06 μg/ml and from 0.25 to 0.5 μg/ml, respectively [33]. These results suggest
that ozenoxacin has a potent bactericidal activity against both levofloxacin-susceptible and levofloxacin-resistant
P. acnes, a microorganism not included in the present study. A 2% lotion formulation of ozenoxacin has been
approved since 2015 in Japan for treatment of inflamed acne.
In this study, the quinolones (ozenoxacin, ciprofloxacin, levofloxacin and moxifloxacin) exhibited comparable
activity against Enterobacteriaceae, whereas ozenoxacin was the most active quinolone against E. cloacae, E. coli, K.
pneumoniae and M. morganii. Ozenoxacin had lower activity than other quinolones against C. freundii, C. koseri,
K. aerogenes, K. oxytoca and S. marcescens, although the differences were relatively small.
As SSTIs are caused mainly by Gram-positive cocci (especially S. aureus and S. pyogenes), the numbers of Gram-
negative isolates derived exclusively from SSTIs were insufficient to compare ozenoxacin with other antibacterial
agents. Moreover, other commonly used topical antibiotics such as mupirocin [34] and fusidic acid [35] have no or
limited activity against Gram-negative isolates. The vast majority of Haemophilus spp. and M. catarrhalis isolates
were derived from RTIs. Nevertheless, irrespective of the source, ozenoxacin was highly active against all Haemophilus
spp. (0.03 mg/l), H. influenzae (0.015 mg/l) and M. catarrhalis (MIC90 of 0.008 mg/l), and was somewhat less
active against H. parainfluenzae (0.25 mg/l).
Conclusion
In conclusion, ozenoxacin was shown to be a potent antibacterial agent against Gram-positive (staphylococci and
streptococci) isolates and showed activity against some Gram-negative isolates. The high activity of ozenoxacin
in staphylococcal and streptococcal spp. including methicillin and quinolone-resistant strains most commonly
associated with childhood impetigo suggests that ozenoxacin may be a valuable alternative to other topical antibiotics
in the eradication of these same bacterial species derived from SSTIs.
Summary points
• Ozenoxacin, a novel nonfluorinated quinolone with bactericidal activity, is approved in the USA, Canada and 12
EU countries as a 1% cream formulation for treatment of impetigo and in Japan as a 2% lotion formulation for
treatment of superficial skin infections and acne.
• During development of ozenoxacin, surveillance studies compared its in vitro antibacterial activity with that of
other topical and systemic antibacterial agents.
• In 2010, a total of 10,054 Gram-positive and Gram-negative isolates were collected from 128 centers worldwide;
isolates were derived mainly from skin and soft tissue infections (SSTIs; 44.8%) and respiratory tract infections
(38.1%).
• Minimum inhibitory concentrations were determined for 23 and 13 antimicrobial agents, respectively, using
standard broth microdilution methods.
• Ozenoxacin exhibited high in vitro activity against susceptible, and methicillin- or levofloxacin-resistant,
Gram-positive bacteria (Staphylococcus aureus, coagulase-negative staphylococci, β-haemolytic streptococci,
viridans streptococci, enterococci and Streptococcus pneumoniae isolates).
• In the case of Gram-positive SSTI isolates, ozenoxacin was generally more active than mupirocin or fusidic acid
and other quinolones.
• Ozenoxacin showed one or two dilutions less activity against Enterobacteriaceae isolates, except for Escherichia
coli, than other quinolones tested.
• In the case of Gram-negative SSTI isolates, no comparisons of ozenoxacin were made with mupirocin and fusidic
acid as these antibiotics are not active against these bacteria.
• Ozenoxacin is a potent antimicrobial agent mainly against susceptible and resistant strains of Gram-positive
isolates (staphylococci and streptococci), and shows activity against some Gram-negative isolates.
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